Vanguard Global Advisers’s Benitec Biopharma BNTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$129K Buy
12,858
+4,198
+48% +$51.3K ﹤0.01% 2658
2026
Q2
$116K Hold
8,660
– – ﹤0.01% 2717
2026
Q1
$92.2K Hold
8,660
– – ﹤0.01% 2760

Other funds holding BNTC

Vanguard Global Advisers's BNTC Position: Q3 2026 in Review

Vanguard Global Advisers increased its Benitec Biopharma (BNTC) stake by 48% in Q3 2026, buying an estimated $51.3K and bringing the position to 12,858 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

Vanguard Global Advisers first reported a position in BNTC in Q1 2026 and has held it in 3 quarters since. 91 funds tracked by Wall St. Rank hold BNTC as of Q3 2026.

  • Vanguard Global Advisers held 12,858 shares of Benitec Biopharma worth $129K as of Q3 2026.
  • Vanguard Global Advisers bought 4,198 Benitec Biopharma shares in Q3 2026, an estimated $51.3K.
  • Benitec Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2658 holding.
  • Vanguard Global Advisers first reported a position in Benitec Biopharma in Q1 2026 and has held it in 3 quarters since.
  • 91 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.